Nothing Special   »   [go: up one dir, main page]

KR960705038A - 자기 면역 질환에 관련된 프로토콜에서 미엘린 올리고덴드로시트 당 단백질 및 그의 펩타이드 부분들의 용도(users of myelin oligodendrocyte glycoprotein and peptide portions thereof in protocols related to autoimmune desease) - Google Patents

자기 면역 질환에 관련된 프로토콜에서 미엘린 올리고덴드로시트 당 단백질 및 그의 펩타이드 부분들의 용도(users of myelin oligodendrocyte glycoprotein and peptide portions thereof in protocols related to autoimmune desease)

Info

Publication number
KR960705038A
KR960705038A KR1019960701093A KR19960701093A KR960705038A KR 960705038 A KR960705038 A KR 960705038A KR 1019960701093 A KR1019960701093 A KR 1019960701093A KR 19960701093 A KR19960701093 A KR 19960701093A KR 960705038 A KR960705038 A KR 960705038A
Authority
KR
South Korea
Prior art keywords
mog
peptide
human
seq
fragment
Prior art date
Application number
KR1019960701093A
Other languages
English (en)
Korean (ko)
Inventor
디복스 브리지트
비. 로트바드 조나단
스밀레크 도운
Original Assignee
스테시 엘. 채닝
이뮤로직 파마시티컬 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스테시 엘. 채닝, 이뮤로직 파마시티컬 코포레이션 filed Critical 스테시 엘. 채닝
Publication of KR960705038A publication Critical patent/KR960705038A/ko

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Rehabilitation Therapy (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
KR1019960701093A 1993-09-03 1994-09-01 자기 면역 질환에 관련된 프로토콜에서 미엘린 올리고덴드로시트 당 단백질 및 그의 펩타이드 부분들의 용도(users of myelin oligodendrocyte glycoprotein and peptide portions thereof in protocols related to autoimmune desease) KR960705038A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11682493A 1993-09-03 1993-09-03
US08/116,824 1993-09-03
PCT/US1994/010257 WO1995006727A2 (en) 1993-09-03 1994-09-01 Uses of myelin oligodendrocyte glycoprotein and peptide portions thereof in protocols related to autoimmune disease

Publications (1)

Publication Number Publication Date
KR960705038A true KR960705038A (ko) 1996-10-09

Family

ID=22369451

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960701093A KR960705038A (ko) 1993-09-03 1994-09-01 자기 면역 질환에 관련된 프로토콜에서 미엘린 올리고덴드로시트 당 단백질 및 그의 펩타이드 부분들의 용도(users of myelin oligodendrocyte glycoprotein and peptide portions thereof in protocols related to autoimmune desease)

Country Status (9)

Country Link
EP (1) EP0716696A1 (ja)
JP (1) JPH09502346A (ja)
KR (1) KR960705038A (ja)
AU (1) AU7725894A (ja)
CA (1) CA2170901A1 (ja)
FI (1) FI961000A (ja)
NO (1) NO960858D0 (ja)
NZ (1) NZ273813A (ja)
WO (1) WO1995006727A2 (ja)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10504039A (ja) * 1994-10-25 1998-04-14 イミユロジク・フアーマシユーチカル・コーポレーシヨン 多発性硬化症のための組成物および治療法
AU5565896A (en) * 1995-05-02 1996-11-21 Alexion Pharmaceuticals, Inc. Modified myelin protein molecules
CA2250361A1 (en) * 1996-03-28 1997-10-02 Barbara Wallner Myelin oligodendrocyte glycoprotein peptides and uses thereof
WO1998033912A1 (en) * 1997-01-30 1998-08-06 Human Genome Sciences, Inc. MYELIN OLIGODENDROCYTE GLYCOPROTEIN-LIKE PROTEIN (MOGp) AND METHODS OF USE
SE9703287D0 (sv) * 1997-09-11 1997-09-11 Astra Ab Peptides
ZA9810133B (en) * 1997-11-07 1999-05-17 Biogen Inc BMOG a novel protein member of the myelin-oligodendrocyte glycoprotein family and its use for ummonomodulatory purposes
US6333033B1 (en) * 1998-08-26 2001-12-25 The Regents Of The University Of California Autoantibody inhibitors
CN1301756A (zh) * 1999-12-29 2001-07-04 复旦大学 一种新的多肽——髓磷脂p0蛋白14和编码这种多肽的多核苷酸
CN1352087A (zh) * 2000-11-02 2002-06-05 上海博德基因开发有限公司 一种新的多肽——人糖蛋白42和编码这种多肽的多核苷酸
WO2007008933A2 (en) * 2005-07-11 2007-01-18 Carantech Biosciences, Inc. Compositions and methods comprising complex alternative splice variants of myelin/oligodendrocyte genes (mogs) and antibodies directed thereto
CN101897964B (zh) * 2009-04-27 2013-04-10 中国农业大学 一种预防自身免疫疾病的药物
WO2013020914A1 (en) * 2011-08-10 2013-02-14 Celares Gmbh Peg-conjugated peptides
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
AU2015249328B2 (en) * 2014-04-24 2019-01-17 University Of Florida Research Foundation, Inc. AAV-based gene therapy for multiple sclerosis
CA3048601A1 (en) * 2016-12-26 2018-07-05 Kyowa Hakko Kirin Co., Ltd. Antibody which binds to myelin oligodendrocyte glycoprotein
US11334352B1 (en) 2020-12-29 2022-05-17 Kpn Innovations, Llc. Systems and methods for generating an immune protocol for identifying and reversing immune disease

Also Published As

Publication number Publication date
NO960858L (no) 1996-03-01
EP0716696A1 (en) 1996-06-19
NZ273813A (en) 1998-05-27
WO1995006727A3 (en) 1995-04-13
FI961000A0 (fi) 1996-03-04
WO1995006727A2 (en) 1995-03-09
AU7725894A (en) 1995-03-22
FI961000A (fi) 1996-03-04
CA2170901A1 (en) 1995-03-09
NO960858D0 (no) 1996-03-01
JPH09502346A (ja) 1997-03-11

Similar Documents

Publication Publication Date Title
KR960705038A (ko) 자기 면역 질환에 관련된 프로토콜에서 미엘린 올리고덴드로시트 당 단백질 및 그의 펩타이드 부분들의 용도(users of myelin oligodendrocyte glycoprotein and peptide portions thereof in protocols related to autoimmune desease)
Jacob et al. Binding of a monoclonal anti-DNA autoantibody to identical protein (s) present at the surface of several human cell types involved in lupus pathogenesis.
Martin et al. A metabolite of halothane covalently binds to an endoplasmic reticulum protein that is highly homologous to phosphatidylinositol-specific phospholipase C-α but has no activity
EP0728146B1 (en) Conotoxin peptides
Kaul et al. Amino acid sequence of the N alpha-terminal 201 residues of human erythrocyte membrane band 3.
KR960706560A (ko) 인화 항체 및 이것의 사용 방법(humanized antibodies and uses thereof)
KR950032279A (ko) 인체의 프로그램된 세포 사멸과 관련 있는 펩티드 및 이를 암호하는 디엔에이(dna)
RU2432360C2 (ru) Вариант еро, обладающий повышенным сродством связывания с рецептором и сниженным антигенным потенциалом, днк, кодирующая такой вариант еро, рекомбинантный экспрессионный вектор, содержащий такую днк, клетка-хозяин, трансформированная или трансфектированная таким вектором, способ получения такого варианта еро и фармацевтическая композиция, содержащая такой вариант еро
Lorenz et al. T cell recognition of bovine ribonuclease. Self/non-self discrimination at the level of binding to the I-Ak molecule.
RU2178797C2 (ru) Новые пептиды, являющиеся производными аутоантигена, предназначенные для использования в иммунотерапии аутоиммунных заболеваний
US5633347A (en) Conotoxin peptides
US5595972A (en) Conotoxin peptides
CA2092541A1 (en) Antagonists of human gamma interferon
DE3584775D1 (de) Zusammensetzung zur behandlung von an haemophilia-a-inhibitor leidenden kranken.
Chatterjee et al. Homology of adenoviral E3 glycoprotein with HLA-DR heavy chain.
KR920012440A (ko) 인간 인터류킨-5 수용체
DE69607034D1 (de) Pcna bindende substanz
KR960705583A (ko) Mhc 단백질의 원핵세포내 형질발현(prokaryotic expression of mhc proteins)
Cunningham et al. Structure of murine histocompatibility antigens
US5589340A (en) Process and primers for identifying nucleic acids encoding A-lineage conotoxin peptides
Imamura et al. A novel nonmuscle alpha-actinin. Purification and characterization of chicken lung alpha-actinin.
Kefalides et al. Heterogeneity of antibodies in Goodpasture syndrome reacting with type IV collagen
Babe et al. Epitopes on the major capsid protein of simian virus 40
KR930703444A (ko) 어류 황체화 호르몬-방출 호르몬 동족체
Ametani et al. Antibody response of three different strains of mice to αs1-casein analyzed by using proteolytic and synthetic peptides

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid